Sorafenib in Combination With RAD001 in Advanced Solid Tumors Selected on Molecular Targets

PHASE1/PHASE2SuspendedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

September 30, 2012

Study Completion Date

December 31, 2012

Conditions
Advanced Solid Tumors
Interventions
DRUG

RAD001 in combination with sorafenib

"Phase I / Dose escalation: during the first cycle RAD001 (2.5-10 mg/day) will be administered alone, once a day, on days 1-14 to allow PK-profiling of the drug. From day 15 sorafenib administration (400-800 mg/day) twice a day will be added.~The cycle 1 will last 6 weeks, subsequent cycles will last 4 weeks (the 2 drugs administered in combination from day 1 to day 28).~Phase II: The drugs will be administered at the Recommended Dose and each treatment cycle will last 4 weeks."

Trial Locations (1)

20141

Istituto Europeo di Oncologia,, Milan

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

Novartis

INDUSTRY

collaborator

Bayer

INDUSTRY

lead

Southern Europe New Drug Organization

OTHER